ect | CARLAT PUBLISHING

CARLAT WEBINAR

ECT: Update and Comprehensive Review

November 3, 2022

0.50 CME Credits. Advances in ECT have made it safer, more comfortable, and with a better cognitive profile that allowed for its use other than just as a last resort.

RESEARCH UPDATE

Do White Matter Hyperintensities Predict Memory Loss with Electroconvulsive Therapy?

October 1, 2022

Dax Volle, MD

Dax Volle, MD. Dr. Volle, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

We can continue to recommend ECT to patients with severe white matter hyperintensities and cognitive impairment, as cognition seems to return to baseline following ECT.

How to Identify and Treat Apathy and Late-Life Depression

October 1, 2022

Rehan Aziz, MD and Julia Cromwell, MD

Rehan Aziz, MD. associate program director, geriatric psychiatry fellowship program, Jersey Shore University Medical Center; associate professor of psychiatry and neurology, Hackensack Meridian School of Medicine, Nutley, NJ. Julia Cromwell, MD. Inpatient geriatric psychiatrist, Mass General Brigham Salem Hospital, Salem, MA. Dr. Aziz and Dr. Cromwell, authors of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

We provide tips on distinguishing between apathy and depression, as well as recommendations on how to manage these disorders.

SAINT TMS Cleared for Treatment-Resistant Depression

September 12, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

On 9/6/22 the FDA approved Stanford’s SAINT Neuromodulation, an accelerated version of TMS that has raised hopes with unusually high remission rates.

Structural Brain Changes After ECT for Depression

April 5, 2022

Chris Aiken, MD and Batya Swift Yasgur, MA, LSW

Chris Aiken, MD Batya Swift Yasgur, MA, LSW The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How does ECT change the brain? A systemic review offers up some answers.

Electroconvulsive Therapy: A Primer

March 23, 2022

Stephen J. Seiner, MD

Stephen J. Seiner, MD Director of neurotherapeutics, McLean Hospital. Belmont, MA. Dr. Seiner has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Seiner runs one of the busiest ECT programs in the country and speaks to us about recent innovations in the procedure. He also tells us which patients are the best candidates and shares tips for how to prolong ECT’s benefits.

Melatonin vs Memantine for ECT-Related Cognitive Impairment

September 13, 2021

Anne Li, MD.

Anne Li, MD. Dr. Li has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Memantine appears more effective than melatonin in reducing post-ECT cognitive impairment.

Pilot Study of Ketamine vs ECT for Major Depression

September 10, 2021

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The first head-to-head comparison reveals a subtle difference between these two therapies

ECT Worked: Now What?

August 3, 2021

Michael Posternak, MD.

Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Your patient has recovered from depression with ECT, but their chances of going back into it are high (80%). In this article, learn 3 ways to reduce that risk.

Getting Uncomfortable with Esketamine

January 13, 2020

Nolan Williams, MD

Nolan Williams, MD

Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA. Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University.